PDC*line Pharma and partners receive €8.1M from Walloon region and Wallonia health cluster BioWin for personalized therapeutic vaccine project

  • PDC*neo+ project aims to develop personalized therapeutic...
Press releases

We are very pleased to announce the publication of a new scientific paper in the peer-reviewed journal "The Journal of Immunology". Title of the article is: "Development of a New Off-the-Shelf...

In the press

PDC*line Pharma completes enrolment of four cohorts of patients     
in PDC-LUNG-101 phase I/II clinical trial.

Total of 67 patients dosed in four cohorts in PDC-LUNG-101 trial with PDC*lung01...

Press releases

We are very pleased to announce the publication of a a new article with an interview of our CEO Eric Halioua published this week in the magazine PharmaBoardroom, the global platform for healthcare &...

In the press

Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from ongoing PDC-LUNG-101 clinical trial


We are very pleased to announce that a new article, following an interview...

In the press

PDC*line Pharma will be presenting a poster in the “Therapeutic Vaccination” session of the 20th Cancer IMmunoTherapy (CIMT) annual meeting taking place from 3 to 5 May 2023, in Mainz (Germany). The...

Forum

We are delighted to announce that our CEO will be presenting at the 6th Europe Neoantigen Summit 2023 hosted by Hanson Wade in Amsterdam (Netherlands) from April 24-26th! He will be presenting PDC...

Forum

We are very pleased to inform you about the publication of a new scientific paper in the peer-reviewed journal "Genes and Cancer" as a "Research Perspective". Article is entitled: Leveraging a...

In the press

We are very pleased to inform you about the publication of a new scientific article in the "International Journal of Molecular Sciences" in a special issue entitled "Dendritic Cell and Cancer Therapy...

In the press

Treatment with PDC*lung01 induces anti-tumor immune response in significant number of patients which appears to be enhanced by combination with pembrolizumab


Liège, Belgium, and Grenoble, France...

Press releases